Biochemistry
Research has identified a key mechanism underlying therapeutic resistance to c-Met/receptor tyrosine kinase (RTK) inhibitors in renal cancer. According to a new study from Dana-Farber Cancer Institute, the upregulation of AXL and c-Met is highly prevalent in renal cell carcinoma (RCC) cells. The study found that prolonged treatment with
Biochemistry
Research conducted at the National Cancer Institute has shed new light on the role of Kaposi sarcoma-associated herpesvirus (KSHV) protein K5 in preventing cell death during lytic replication. The study, published in the Journal of Virology, found that K5 is a substrate for caspases and plays a crucial role in
Biochemistry
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, characterized by high incidence and mortality rates. Researchers at the Affiliated Hospital of Zunyi Medical University conducted a study to explore the role of circular RNAs (circRNAs) in NSCLC, which may serve as potential biomarkers and therapeutic
Biochemistry
Researchers at China Medical University have made a significant discovery in understanding the mechanisms of non-small cell lung cancer (NSCLC) progression and cisplatin resistance. Their study, published in The FASEB Journal, reveals that the interaction between disheveled binding antagonist of b-catenin 3 (DACT3) and disheveled 1 (DVL1) inhibits the DVL1-induced
Biochemistry
Research has shed new light on the crucial form of synaptic plasticity essential for memory and learning, known as Long-Term Potentiation (LTP). A study conducted by researchers at Northwestern University Feinberg School of Medicine has highlighted the significance of the secretory pathway, particularly the endoplasmic reticulum (ER) and Golgi trafficking
Biochemistry
Researchers at Affiliated Hospital of North Sichuan Medical College have conducted a study to investigate the role of Phosphatidylinositol glycan anchor biosynthesis class U (PIGU) in esophageal squamous cell carcinoma (ESCC). The study found that PIGU is highly expressed in ESCC and is associated with tumor growth, lymphatic metastasis, and
Biochemistry
Researchers from M.S. Ramaiah University of Applied Sciences have discovered a novel approach to overcoming resistance to osimertinib, a third-generation epidermal growth factor receptor inhibitor, in non-small cell lung cancer (NSCLC). By combining osimertinib with epigallocatechin-3-gallate (EGCG), a green tea polyphenol, they found that the combination therapy significantly enhanced
Biochemistry
Researchers at the National Cancer Institute (NCI) have made a significant breakthrough in the field of non-small cell lung cancer (NSCLC) research. According to a study published on bioRxiv, the team discovered a potential therapeutic strategy for NSCLC, irrespective of the mutation status of tyrosine kinase (TK)-encoding genes. The
Biochemistry
Researchers at Shanghai University of Traditional Chinese Medicine have conducted a study on the impact of Traditional Chinese Medicine (TCM) therapy on postoperative recurrence and metastasis prevention in patients with stage IIIA non-small cell lung cancer. The study analyzed real-world data from patients who underwent radical surgery between January 2016
Biochemistry
New research out of Universita Cattolica del Sacro Cuore in Rome, Italy, has found that circulating tumor DNA (ctDNA) may hold the key to more accurate and innovative detection and treatment of early-stage non-small cell lung cancer (NSCLC). The study, published in the journal Genes, highlights the potential of ctDNA
Biochemistry
Investigators at Vanderbilt University Medical Center have published new research on the impact of the tumor-specific EphA2 receptor tyrosine kinase on non-small cell lung cancer (NSCLC). According to the report, EphA2 plays a crucial role in tumor growth and metastasis and has been identified as a viable target for many
Biochemistry
Researchers from the Boonshoft School of Medicine have made a significant discovery in the treatment of non-small cell lung cancer (NSCLC). By combining immune checkpoint inhibitors (ICIs) and anti-angiogenic pharmacologic agents, they have shown promising results in patients with NSCLC. This breakthrough has the potential to offer a new therapeutic
